Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 10/20 | 0.78 |
| ▸ | MAPT | P10636 | 8/20 | 0.78 |
| ▸ | POLB | P06746 | 3/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12286344 | 0.91 | RXFP1 (0.84) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12288668 | 0.90 | RXFP1 (0.82) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12287169 | 0.89 | RXFP1 (0.80) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12286278 | 0.88 | RXFP1 (0.86) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12287171 | 0.88 | RXFP1 (0.78) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12286110 | 0.87 | RXFP1 (0.78) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12285304 | 0.87 | RXFP1 (0.77) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12286109 | 0.87 | RXFP1 (0.77) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12287163 | 0.86 | RXFP1 (0.75) | RXFP1TP53MAPTPOLBTDP1 | |
| SCHEMBL12285230 | 0.86 | RXFP1 (0.75) | RXFP1TP53MAPTPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927561-B2 | Pyrimidinedione anti-viral compounds | Kineta, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927561-B2 | Pyrimidinedione anti-viral compounds | Kineta, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130045229-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045229-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011133722-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045229-A1 | Anti-Viral Compounds | MAVS, EIF2AK2, IRF3 | RXFP1 3056/4885TP53 1338/4885MAPT 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.